Richard D. Francis - 05 Jun 2026 Form 4 Insider Report for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)

Reporting relationship: President and CEO
Issuer ticker: TEVA
Reported as of: 05 Jun 2026
Net transaction value: -$211,356
SEC form: 4
Accepted by SEC: 08 Jun 2026, 16:01:07 UTC
Prior SEC filing: 09 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Dov Bergwerk as attorney-in-fact for Richard D. Francis

Key filing fact

Richard D. Francis filed Form 4 for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) on 08 Jun 2026.

Key facts

This page summarizes Richard D. Francis's Form 4 filing for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 08 Jun 2026, 16:01.

Change

Previous filing in this sequence was filed on 09 Mar 2026.
Current net transaction value: -$211,356.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001673277 Primary reporting owner

Francis Richard D

Relationship: President and CEO
Address: C/O TEVA PHARMACEUTICAL INDUSTRIES LTD., 124 DVORA HANEVI'A ST.,, TEL AVIV, ISRAEL
Signature: /s/ Dov Bergwerk as attorney-in-fact for Richard D. Francis
Signature date: 08 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TEVA transaction

Ordinary Shares

Options Exercise

Transaction value
Shares: +13,043
Change %: +1.1%
Price
Shares after: 1,183,682
Date: 05 Jun 2026
Ownership: Direct
Footnotes: F1, F2

TEVA transaction

Ordinary Shares

Sale

Transaction value: $211,356
Shares: -6,153
Change %: -0.52%
Price: $34.35
Shares after: 1,177,529
Date: 05 Jun 2026
Ownership: Direct
Footnotes: F1, F3, F4

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TEVA transaction Derivative

Restricted Share Units

Options Exercise

Transaction value
Shares: -13,043
Change %: -25%
Price: $0.000000^*
Shares after: 39,130
Date: 05 Jun 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 13,043
Exercise price
Footnotes: F1, F2, F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 5 footnotes

Footnote F1

The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Footnote F2

Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Footnote F3

The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2025.

Footnote F4

Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.

Footnote F5

Restricted share units were granted on June 5, 2025, with 13,043 vested on June 5, 2026, 13,043 vesting on each of June 5, 2027 and June 5, 2028, and 13,044 vesting on June 5, 2029.